Once the Pharmas start sniffing out a profit again, then we will see new studies and products trickling out.
Schering released a new long ester test "Nebido" specifically for HRT a while back.It was first approved for HRT in Finland in 2003. Indevus licensed U.S. rights to Nebido in July of 2005. They are conducting pharmacokinetic studies they expect to be done in May of this year. It probably wont be available to consumers (eer patients) until next year at best (overly optimistic). Just an example, Stuff takes time...NEBIDO contains 1000 mg testosterone undecanoate in a novel formulation. After administration of NEBIDO, testosterone levels remain within the physiological range for approximately 12 weeks.
Eventually we will see inhaled steroids and such (already available with insulin). The demand just isn't large enough yet. HRT in men at around 35-40 will become as common as women receiving HRT now (which is commonplace). Unfortunately, society evolves slower than science.